Poxel (POXEL) Q1 2025 earnings summary

Executive summary

• TWYMEEGⓇ gross sales in Japan for FY 2024 reached JPY 7.6 billion (EUR 47.2 million), a 65% increase over FY 2023 and in line with guidance.

• Regulatory approval in April 2025 allows TWYMEEGⓇ to be prescribed to type 2 diabetic patients with moderate to severe renal impairment in Japan.

• Poxel reported consolidated revenue of EUR 1,066 thousand for Q1 2025, up 137% year-over-year, driven by TWYMEEGⓇ royalties.

• Ongoing negotiations with creditors and potential partners to ensure operational continuity and unlock pipeline value.

Financial highlights

• Q1 2025 consolidated revenue was EUR 1,066 thousand, compared to EUR 449 thousand in Q1 2024.

• TWYMEEGⓇ gross sales in Japan for the quarter ended March 2025 totaled JPY 1.9 billion (EUR 12 million).

• Poxel began receiving 10% royalties on TWYMEEGⓇ net sales in FY 2024; expects at least 12% royalties in FY 2025.

• All positive net royalties are dedicated to bond repayment per the OrbiMed agreement.

Outlook and guidance

• Sumitomo Pharma forecasts FY 2025 TWYMEEGⓇ gross sales of JPY 11.2 billion (EUR 69.4 million), a 47% increase over FY 2024.

• Poxel anticipates escalating double-digit royalties and additional sales-based payments upon reaching contractual thresholds.

• Cash runway is estimated through June 2025, pending outcomes of creditor negotiations.